Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses: 2016-2024

Historic Change in Accured Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $17.5 million.

  • Crinetics Pharmaceuticals' Change in Accured Expenses rose 866.13% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 147.08%. This contributed to the annual value of $17.5 million for FY2024, which is 19.75% up from last year.
  • As of FY2024, Crinetics Pharmaceuticals' Change in Accured Expenses stood at $17.5 million, which was up 19.75% from $14.6 million recorded in FY2023.
  • Crinetics Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $17.5 million during FY2024, with a 5-year trough of $2.7 million in FY2020.
  • For the 3-year period, Crinetics Pharmaceuticals' Change in Accured Expenses averaged around $14.4 million, with its median value being $14.6 million (2023).
  • Data for Crinetics Pharmaceuticals' Change in Accured Expenses shows a peak YoY surged of 291.24% (in 2020) over the last 5 years.
  • Crinetics Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $2.7 million in 2020, then soared by 131.11% to $6.3 million in 2021, then spiked by 74.70% to $11.0 million in 2022, then soared by 33.24% to $14.6 million in 2023, then climbed by 19.75% to $17.5 million in 2024.